Societe Generale Increases Boiron (OTCMKTS:BOIRF) Price Target to €53.00

Boiron (OTCMKTS:BOIRFGet Rating) had its target price boosted by Societe Generale from €51.00 ($52.04) to €53.00 ($54.08) in a report issued on Friday, The Fly reports. They currently have a buy rating on the stock.

Boiron Price Performance

Shares of BOIRF opened at $46.71 on Friday. The business’s 50 day moving average is $44.30 and its two-hundred day moving average is $43.41. Boiron has a 52-week low of $41.10 and a 52-week high of $52.00.

About Boiron

(Get Rating)

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders.

See Also

The Fly logo

Receive News & Ratings for Boiron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boiron and related companies with MarketBeat.com's FREE daily email newsletter.